To view this email as a web page, click here

   Home

Subscribe

Advertise

 

 

 

 

March 09, 2018

Today's Rundown

Featured Story

MSKCC’s Maura Dickler to become Eli Lilly’s new late-stage cancer R&D lead

Memorial Sloan Kettering Cancer Center’s Maura Dickler, M.D., has been lined up as Lilly’s new VP of late-phase development in oncology.

Top Stories

AM-Pharma still on track with sepsis drug despite mixed phase 2 readout

The Dutch biotech's recAP candidate has shown a 40% reduction in mortality in patients with sepsis-related acute kidney injury.

Kapeller leaves Nimbus, ending CSO stint defined by virtual drug discovery successes

Rosana Kapeller, M.D., Ph.D., has left Nimbus Therapeutics after eight years in the CSO post. Kapeller departs having helped put virtual drug discovery on the map and land deals with Celgene, Genentech and Gilead.

MyoKardia delivers in midstage trial, revs up for phase 3

MyoKardia's hypertrophic cardiomyopathy drug, mavacamten, met primary and secondary endpoints in a phase 2 trial. The data will inform dosing in the upcoming pivotal study.

AI-driven drug discovery startup Atomwise raises $45M series A

Artificial intelligence-driven drug discovery has attracted many investments lately. Atomwise, the first company to commercialize deep neural networks for drug discovery, joined the growing list with a $45 million series A.

WuXi NextCODE and Google Cloud partner to enhance global genomic access

Genomics giant WuXi NextCODE is partnering with Google Cloud to establish a global platform standard for using genome data to advance health worldwide.

EuroBiotech Report—Reed exits Roche, Autolus CAR-T IPO, U.K. seeks EMA role, cancer vaccines and cystic fibrosis data

In this week's EuroBiotech Report, Reed leaves Roche, Autolus files for Nasdaq IPO, the U.K. pitches for an ongoing EMA role and more. 

FiercePharmaAsia—Merck-Eisai’s Lenvima deal, JW’s $90M series A, novel HIV drug

Merck signed a deal potentially worth $5.8 billion for half of Lenvima's sales; Juno and WuXi AppTec's CAR-T joint venture got $90 million in a series A; the FDA approved TaiMed Biologics’ novel HIV drug Trogarzo manufactured by WuXi Biologics; plus more pharma industry news from Asia.

Chutes & Ladders—Parexel co-founder ends 35-year run as CEO

Parexel co-founder Joseph von Rickenbach hands the reins to former INC Research helmsman Jamie Macdonald, Roche promotes William Pao to replace departing John Reed as pRED head, Moderna loses its CSO of infectious diseases, plus more hirings, firings and retirings throughout the industry.

Resources

[Webinar] Driving Market Access through Patient Advocacy: Trends & Opportunities

There’s no magic bullet to successful access but insights from patient advocates and industry experts can help shape future strategies. Learn how in this webinar. Sign up now!

[Whitepaper] Medical Device Innovation: Are You Outrunning The Competition?

The competitive landscape in medical device R&D is tough. And simply investing in R&D is no guarantee for profitability. So how do you accelerate time-to-market?

[Whitepaper] How Life Sciences Companies Use Box for Regulated Content in the Cloud

Learn how biopharma and medical device companies can now collaborate on, manage and distribute regulated clinical, lab and manufacturing content in Box. That means all of your content is standardized on a single content repository that meets regulatory and compliance standards, so you can eliminate inefficient silos, enable seamless collaboration and accelerate the validation process.

[Whitepaper] CFO's, Is This Part Of Your Corporate TO DO List?

Employee stock option trading & administration, Restricted stock transactions (Rule 144), Affiliated trading plans (10b5-1), Directed share plans, Equity comp plan administration — private to public

[Whitepaper] Choosing the Right Solution: Improving the Site Feasibility Process

Selecting the right sites to conduct your clinical trials will determine the success or failure of meeting your enrollment goals.

[Whitepaper] How Do Sponsors Ensure Quality in Global Clinical Trials?

Global clinical trials are the trend and gaining in popularity, but running a global trial is not a straightforward process. This white paper explores some of the challenges associated with global clinical trials and considerations for ensuring that the collected data comply with the trial's overall objectives.

[Webinar] Validating a 7 Day Membrane Filtration Sterility Test using Celsis®

Join us as we discuss how Charles River Celsis® helped Labor L+S AG validate a 7-day membrane filtration sterility test using existing protocols.

[Infographic] Evolution of Flexible Commercial Biologics Manufacturing

Learn how Catalent Biologics is paving the way for flexible biologics development and manufacturing through advanced technologies and fully integrated multi-product facility.

[eBook] Developing Site-specifically Modified ADCs: Using a Chemoenzymatic Approach

Download the eBook to get articles from various Elsevier journals highlighting developments in ADC technology.

[Article] Optimizing titer and use of a specific enzyme for generating a fully processed antibody

Learn how cell development and process scale-up can be optimized for antibodies requiring additional processing.

[Webinar] Within-Subject Clinical Trials: Intro to New Methods & Stat. Models

In this webinar, we will introduce the rapidly-evolving within-subject clinical trial (WSCT) methods for early phase evidence generation that require fewer people, less time, and usually less funding than traditional early phase methods.

Events

.